Artemisinic Acid Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Total Synthesis, Semi synthesis), By Applications (Antimalarial Injections, Antimalarial Tablets), By Region, By Competition, 2020-2030F

Market Overview

The Global Artemisinic Acid Market, valued at USD 521.90 Million in 2024, is projected to experience a CAGR of 4.11% to reach USD 664.57 Million by 2030. Artemisinic acid, a pivotal sesquiterpene derived primarily from *Artemisia annua L. *, functions as a critical precursor for the semi-synthesis of artemisinin, an active pharmaceutical ingredient essential in antimalarial drugs. The market’s expansion is robustly supported by several key drivers, including the persistent global burden of malaria, which sustains the demand for artemisinin-based combination therapies, and continuous advancements in biotechnological production methods like microbial fermentation, offering enhanced supply chain reliability and cost predictability. Furthermore, increasing investments in research and development exploring diverse therapeutic applications beyond malaria also contribute to market growth.

However, the industry faces notable impediments, such as the emergence of artemisinin resistance in malaria parasites, which necessitates ongoing innovation in drug development. This challenge is compounded by the high prevalence of malaria globally; according to the WHO's World Malaria Report 2024, an estimated 249 million malaria cases occurred worldwide in 2022, leading to 608,000 deaths, underscoring the critical need for effective solutions and the demand for artemisinic acid as a key starting material. Addressing these resistance concerns is paramount for sustained market expansion.

Key Market Drivers

The global artemisinic acid market is significantly influenced by the persistent burden of malaria worldwide and continuous advancements in biotechnological production methods. The enduring health crisis of malaria consistently drives demand for artemisinin-based combination therapies, which in turn elevates the need for artemisinic acid as a crucial precursor. The crisis necessitates a steady supply of effective antimalarial drugs. According to the World Health Organization (WHO), in December 2024, the Malaria Report stated that global malaria cases reached an estimated 263 million in 2023, underscoring the vast and ongoing need for treatment. Simultaneously, advancements in biotechnological production methods significantly enhance supply chain reliability and cost predictability for artemisinic acid. Synthetic biology innovations, particularly engineered microbial fermentation, revolutionize manufacturing. For instance, according to MDPI, in October 2022, "From Plant to Yeast—Advances in Biosynthesis of Artemisinin" noted that optimized fermentation processes allowed artemisinic acid yield to reach 25 grams per liter, offering a scalable and controlled alternative to plant extraction. These improvements mitigate supply volatilities.

The combined influence of these drivers reinforces artemisinic acid's pivotal role in global health. Substantial investment from international bodies further solidifies the market's trajectory, ensuring continued access to essential antimalarial components. According to Africanews, in December 2024, "Malaria cases surge in 2023, says WHO Report" highlighted that $4 billion was allocated globally to combat malaria in 2023, reflecting critical commitment to addressing the disease and supporting demand for effective treatments. This financial backing, coupled with ongoing scientific innovation, is crucial for sustaining the development and availability of antimalarial therapies that rely on artemisinic acid.

Download Free Sample Report

Key Market Challenges

The emergence of artemisinin resistance in malaria parasites poses a significant challenge to the Global Artemisinic Acid Market. This resistance directly undermines the efficacy of artemisinin-based combination therapies, which are currently pivotal for malaria treatment. As parasites develop resistance, the sustained effectiveness of these essential drugs is jeopardized, leading to reduced confidence in artemisinin as a reliable active pharmaceutical ingredient. This instability threatens the consistent demand for artemisinic acid, its key precursor.

Developing new antimalarial drugs to overcome this resistance represents a substantial financial burden on the pharmaceutical industry. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the estimated cost for researching and developing a new chemical or biological entity was €3,130 million (equivalent to $3,296 million in 2022 dollars) in 2022. This considerable investment, required for ongoing innovation to counteract resistance, diverts resources and increases development timelines, thereby impeding stable market growth for established precursors like artemisinic acid.

Key Market Trends

The prioritization of sustainable production processes is emerging as a critical trend within the global artemisinic acid market. This focus extends beyond mere compliance, reflecting a concerted effort across the pharmaceutical industry to minimize environmental impact and promote ethical manufacturing practices throughout the supply chain. Companies are increasingly investing in green chemistry principles, adopting renewable energy sources, and implementing waste reduction strategies to enhance their ecological footprint. According to Cytiva's 2024 Global Biopharma Sustainability Review, sustainability ranks as the number one priority for 62% of biopharma companies over the next five years, indicating a significant shift towards environmentally conscious operations. This commitment drives innovation in manufacturing techniques, promoting resource efficiency and a reduced reliance on hazardous materials in the production of key pharmaceutical precursors like artemisinic acid.

Another significant trend involves the development of patient-friendly antimalarial therapies. This area of innovation aims to improve patient adherence to treatment regimens and enhance drug accessibility, particularly for vulnerable populations such as infants and young children. New formulations and simplified dosing schedules are crucial in combating the persistent challenge of malaria. For example, according to GSK and Medicines for Malaria Venture, in July 2024, Brazil and Thailand became the first malaria-endemic countries to launch tafenoquine, a new single-dose medicine for *Plasmodium vivax* malaria prevention. Such advancements, including child-friendly formulations and single-dose options, are vital for ensuring effective treatment delivery and ultimately reducing the burden of malaria by improving treatment outcomes and preventing disease relapse.

Segmental Insights

Within the Global Artemisinic Acid Market, Antimalarial Tablets stand out as the fastest-growing segment, primarily driven by the persistent and widespread burden of malaria, particularly in developing and underdeveloped economies. This segment's rapid expansion is attributed to the increasing global demand for Artemisinin-based Combination Therapies (ACTs), which rely on artemisinic acid as a critical precursor for their active ingredient. ACTs are recognized as the primary treatment for uncomplicated *Plasmodium falciparum* malaria due to their proven efficacy against drug-resistant strains. Furthermore, the growth is significantly bolstered by ongoing malaria eradication initiatives from international public health organizations, such as the World Health Organization (WHO) and UNICEF, which focus on improving access to effective treatments and raising public awareness. The convenience, affordability, and widespread acceptance of oral tablet formulations also contribute to their increasing adoption in global health programs.

Regional Insights

The Middle East and Africa region leads the global artemisinic acid market primarily due to the significant and persistent burden of malaria, particularly across sub-Saharan Africa. This high disease prevalence directly drives substantial demand for artemisinin-based combination therapies, which are the cornerstone of modern antimalarial treatment recommended by the World Health Organization. Consequently, strong governmental and public health initiatives focused on malaria eradication and improving access to essential medicines contribute to heightened procurement and utilization of artemisinic acid in the region. These collective efforts, coupled with investments in healthcare infrastructure, firmly establish the Middle East and Africa as the dominant market segment.

Recent Developments

• In May 2025, Amyris expanded its industrial footprint by taking full ownership of a Brazilian industrial fermentation plant and investing in the completion of its fourth precision fermentation line. This strategic move enhances the company's internal manufacturing capabilities, allowing for greater control over production and scale-up of biologically derived compounds. The expansion of precision fermentation capacity is a significant development for the global artemisinic acid market, as it directly supports the advanced production methods necessary for semi-synthetic artemisinin and other essential small-molecule drugs.

• In May 2025, Sanofi committed to investing at least $20 billion in the United States through 2030, targeting substantial increases in research and development alongside expanding domestic manufacturing capabilities. This extensive investment aims to bolster the company's capacity for producing key medicines within the U.S. By enhancing its R&D and manufacturing infrastructure, Sanofi, a prominent player in the global pharmaceutical industry, is supporting innovations and production efficiencies that are critical for various essential active pharmaceutical ingredients, including those relevant to the artemisinic acid market's long-term supply stability and innovation.

• In October 2024, Amyris, a synthetic biology company, secured $12.3 million in government funding to address U.S. drug shortages through its innovative synthetic biology platform. This collaboration with the Biopharmaceutical Manufacturing Preparedness Consortium aims to develop up to three essential small-molecule drugs using advanced precision fermentation and organism engineering. This initiative underscores the company's commitment to enhancing domestic pharmaceutical manufacturing capabilities, directly supporting the broader trend within the global artemisinic acid market towards more sustainable and reliable biotechnological production methods for critical active pharmaceutical ingredients.

• In May 2024, Sanofi announced an investment exceeding €1 billion to establish new bioproduction capacity across its sites in France. This significant capital allocation aims to strengthen France's self-sufficiency in manufacturing essential medicines. As a pharmaceutical leader with historical involvement in semi-synthetic artemisinin production, this investment in advanced biomanufacturing capabilities inherently supports the development and scalable production of critical precursor compounds like artemisinic acid, contributing to a more robust global supply chain for antimalarial therapies and other vital drugs.

Key Market Players

• Sanofi SA
• KPC Pharmaceuticals, Inc
• Guilin Pharmaceutical Co., Ltd
• Calyx Chemicals and Pharmaceuticals Ltd.
• Novartis AG
• Ipca Laboratories Ltd.
• Cipla Inc.
• Shin Poong Pharm Co., Ltd.
• Rupus Global Limited
• AdvacarePharma

Report Scope:

In this report, the Global Artemisinic Acid Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Artemisinic Acid Market, By Type:

o   Total Synthesis

o   Semi synthesis

• Artemisinic Acid Market, By Applications:

o   Antimalarial Injections

o   Antimalarial Tablets

• Artemisinic Acid Market, By Region:

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   North America

§  United States

§  Canada

§  Mexico

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Artemisinic Acid Market.

Available Customizations:

Global Artemisinic Acid Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Artemisinic Acid Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]